Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II double-blind study of ZP120 as short-term IV add-on therapy in subacute decompensated chronic heart failure
2004-004801-11Phase 2Completed
- Sponsor
- Zealand Pharma
- Start
- Jan 2005
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in chronic heart failure (CHF) and heart failure (HF) comparing ZP120 + furosemide with Placebo + furosemide (2 arms). Primary endpoint: Increase in diuresis. Started Jan 2005; status: completed.
02
Drugs
SER-100
03
Conditions
chronic heart failure (CHF)heart failure (HF)
Beyond the preview
Go deeper on 2004-004801-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2004-004801-11.